Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia

Neuropsychopharmacology

Volumn 35, Issue 2, 2010, Pages 428-434

  Rapaport, Mark H ^a,b   Bresee, Catherine ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine production; Longitudinal analysis; Medication effects; Schizophrenia; TH 1 immune activation

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MITOGENIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING;

ADULT; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MITOGENS; SCHIZOPHRENIA; SMOKING;

EID: 72449197977     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.145     Document Type: Article

References (55)

1. American Psychiatric Association (1994). The Diagnostic and Statistical Manual of Mental Disorders. DSM-IV: Washington, DC.
2. Arolt V, Rothermundt M, Wandinger KP, Kirchner H (2000). Decreased in vitro production of interferon-gamma and inter-leukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5: 150-158.
3. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995). Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297-302.
4. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Adorni A, Pegoraro M et al (2002). Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26: 33-39.
5. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A et al (2001). Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 47: 293-298.
6. Cheng SM, Lai JH, Yang SP, Tsao TP, Ho LJ, Liou JT et al (2008). Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol. 27 Nov 2008 (e-pub ahead of print.
7. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F et al (1992). Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 4: 239-248.
8. Dunn AJ (2006). Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6: 52-68.
9. First MB (1997). Structured Clinical Interview for DSM-IV Axis I Disorders: SCID-I. American Psychiatric Press: Washington, DC.
10. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G et al (1995). Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52: 668-672.
11. Ganguli R, Rabin BS, Belle SH (1989). Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26: 427-430.
12. Giebelen IA, van Westerloo DJ, LaRosa GJ, de Vos AF, van der Poll T (2007). Local stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the mouse lung. Shock 28: 700-703.
13. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A et al (1999). Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33: 407-418.
14. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H (1995). Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 15: 237-242.
15. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
16. Kim DJ, Kim W, Yoon SJ, Go HJ, Choi BM, Jun TY et al (2001). Effect of risperidone on serum cytokines. Int J Neurosci 111: 11-19.
17. Kim YK, Lee MS, Suh KY (1998). Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 43: 701-704.
18. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ et al (2004). Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 1129-1134.
19. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F et al (2000). Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsycho-pharmacol 10: 119-124.
20. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997). In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26: 221-225.
21. Maes M, Meltzer HY, Bosmans E (1994). Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346-351.
22. Matsunaga K, Klein TW, Friedman H, Yamamoto Y (2001). Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 167: 6518-6524.
23. McAfoose J, Baune BT (2009). Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33: 355-366.
24. Monteleone P, Fabrazzo M, Tortorella A, Maj M (1997). Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71: 11-17.
25. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M (1997). Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247: 308-313.
26. Müller N, Schwarz M (2006a). Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10: 131-148.
27. Müller N, Schwarz MJ (2006b). Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev Neurother 6: 1017-1038.
28. Müller N, Schwarz MJ (2007). The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 269-280.
29. Müller N, Schwarz MJ (2008). COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14: 1452-1465.
30. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Moller HJ et al (2004). COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254: 14-22.
31. Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE (2009). Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 24: 55-68.
32. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B et al (2008). Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res. 18 Aug 2008 (e-pub ahead of print.
33. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al (2005). Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29-38.
34. O'Donnell MC, Catts SV, Ward PB, Liebert B, Lloyd A, Wakefield D et al (1996). Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Res 65: 171-178.
35. Pollmacher T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J (1997). Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154: 1763-1765.
36. Pollmacher T, Hinze-Selch D, Mullington J (1996). Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16: 403-409.
37. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801-808.
38. Rapaport MH, Caligiuri MP, Lohr JB (1997). An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 21: 817-827.
39. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmad-pour O, Dolnak D (2005). Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 57: 1594-1596.
40. Rapaport MH, Doran AR, Nelson DL, McAllister C, Magliozzi JR, Paul SM (1991a). Haloperidol and soluble interleukin-2 receptors. Biol Psychiatry 30: 1063-1064.
41. Rapaport MH, Lohr JB (1994). Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 90: 311-315.
42. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL et al (1994). Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol Psychiatry 35: 767-771.
43. Rapaport MH, McAllister CG, Kirch DG, Pickar D (1991b). The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiatry 29: 715-717.
44. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM (1989). Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch Gen Psychiatry 46: 291-292.
45. Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM (1993). Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 243: 7-10.
46. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H (2000). Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11: 3385-3388.
47. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H (1998). Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 37: 186-193.
48. Rubin RT, Poland RE, Lesser IM (1990). Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects. Biol Psychiatry 27: 1065-1082.
49. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J et al (2000). Specific inhibition of cyclooxygenase 2 restores anti-tumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370.
50. Stone TW, Behan WM (2007). Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res 85: 1077-1085.
51. van Westerloo DJ, Giebelen IA, Florquin S, Bruno MJ, Larosa GJ, Ulloa L et al (2006). The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastro-enterology 130: 1822-1830.
52. Villemain F, Chatenoud L, Guillibert E, Pelicier Y, Bach JF (1987). Decreased production of interleukin-2 in schizophrenia. Ann N Y Acad Sci 496: 669-675.
53. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H (1996). Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279-284.
54. Wisse BE (2004). The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15: 2792-2800.
55. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC (2005). Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30: 1532-1538.